B. Riley Wealth Advisors Inc. Sells 5,744 Shares of Bristol-Myers Squibb (NYSE:BMY)

B. Riley Wealth Advisors Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 3.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 147,366 shares of the biopharmaceutical company's stock after selling 5,744 shares during the quarter. B. Riley Wealth Advisors Inc.'s holdings in Bristol-Myers Squibb were worth $8,335,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $25,000. Fairway Wealth LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $28,000. Transce3nd LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $28,000. Comprehensive Financial Planning Inc. PA bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $34,000. Finally, Tacita Capital Inc bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at $39,000. 76.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BMY shares. UBS Group decreased their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Argus raised Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Finally, William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

BMY stock traded up $0.83 during midday trading on Thursday, reaching $47.80. The company had a trading volume of 10,490,379 shares, compared to its average volume of 13,129,834. The company has a market capitalization of $97.27 billion, a price-to-earnings ratio of -10.81, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The stock has a 50 day moving average price of $50.97 and a 200-day moving average price of $55.54. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Bristol-Myers Squibb's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. Equities research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.19%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.